Evidence map›Paper›PMID 10359665›Full record

ArticleThe Biochemical journal1999

Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

E A Biessen, H Vietsch, E T Rump, K Fluiter, J Kuiper, M K Bijsterbosch, T J van Berkel

Abstract read
In one paragraph

Article in The Biochemical journal, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Article
  3. Oligonucleotide therapies for nonalcoholic steatohepatitis.Molecular therapy. Nucleic acids · 2024
    Review
  4. Tissue pharmacokinetics of antisense oligonucleotides.Molecular therapy. Nucleic acids · 2024
    Article
  5. Trials and Tribulations of MicroRNA Therapeutics.International journal of molecular sciences · 2024
    Review
  6. Review
  7. Clinical Pharmacokinetics of Approved RNA Therapeutics.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Article
  10. Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.Molecular therapy : the journal of the American Society of Gene Therapy · 2020
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Endocytic mechanisms for targeted drug delivery.Advanced drug delivery reviews · 2007
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

E A BiessenDivision of Biopharmaceutics, LACDR, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands. biessen@lacdr.leidenuniv.nl
H Vietsch
E T Rump
K Fluiter
J Kuiper
M K Bijsterbosch
T J van Berkel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-sense oligodeoxynucleotides (ODNs) hold great promise for correcting the biosynthesis of clinically relevant proteins. The potential of ODNs for modulating liver-specific genes might be increased by preventing untimely elimination and by improving the local bioavailability of ODNs in the target tissue. In the present study we have assessed whether the local ODN concentration can be enhanced by the targeted delivery of ODNs through conjugation to a ligand for the parenchymal liver cell-specific asialoglycoprotein receptor. A capped ODN (miscellaneous 20-mer sequence) was derivatized with a ligand with high affinity for this receptor, N2-[N2-(N2,N6-bis{N-[p-(beta-d-galactopyranosyloxy) anilino] thiocarbamyl}-L-lysyl)-N6-(N-{p-[beta-D -galactopyranosyloxy] anilino} thiocarbamyl)-L-lysyl]-N6-[N- (p-{beta-D-galactopyranosyloxy}anilino)thiocarbamyl]-L-lysine (L3G4) (Kd 6.5+/-0.2 nM, mean+/-S.D.). Both the uptake studies in vitro and the confocal laser scan microscopy studies demonstrated that L3G4-ODN was far more efficiently bound to and taken up by parenchymal liver cells than underivatized ODN. Studies in vivo in rats showed that hepatic uptake could be greatly enhanced from 19+/-1% to 77+/-6% of the injected dose after glycoconjugation. Importantly, specific ODN accumulation of ODN into parenchymal liver cells was improved almost 60-fold after derivatization with L3G4, and could be attributed to the asialoglycoprotein receptor. In conclusion, the scavenger receptor-mediated elimination pathway for miscellaneous ODN sequences can be circumvented by direct conjugation to a synthetic tag for the asialoglycoprotein receptor. In this manner a crucial requisite is met towards the application of ODNs in vivo to modulate the biosynthesis of parenchymal liver cell-specific genes such as those for apolipoprotein (a), cholesterol ester transfer protein and viral proteins.

Indexed as

Gene TargetingAcetylglucosamineAnimalsAsialoglycoprotein ReceptorBinding, CompetitiveCells, CulturedColchicineEndocytosisGalactosidesGene Expression RegulationHalf-LifeLigandsLiverLysosomesMaleMicroscopy, ConfocalAcetylglucosamineAsialoglycoprotein ReceptorColchicineGalactosidesLigandsMonensinOligodeoxyribonucleotides, AntisenseReceptors, Cell SurfaceSodium AzideSucrose

Identifiers

PMID10359665
PMCPMC1220312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.